Article
Abbott's UroVysion DNA probe assay has been approved by the FDA for use as an aid in initial diagnosis of bladder cancer in patients with hematuria and suspected of having bladder cancer.
Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB
Key updates from the AUA/ASRM male infertility guideline amendment
FDA grants 510(k) clearance to Ambu’s HD cystoscopy solution
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
Category I CPT code granted to irreversible electroporation for prostate lesions
TikTok content on low testosterone lacks information on future risks, study finds